Abstract
Modern biotechnology has grown over the last 35 years to a maturing industry producing and delivering high-value biopharmaceuticals that yield important medical and economical benefits. The constantly increasing need for biopharmaceuticals and significant costs related to time-consuming R&D work makes this industry risky and highly competitive. This trend is confirmed by the important number of biopharmaceuticals that are actually under development at all stages by all major pharmaceutical industry companies. A consequence of this evolution is an increasing need for development and manufacturing capacity. The build up of traditional – stainless steel – technology is complicated, time consuming and very expensive. The decision for such a major investment needs to be taken early in the development cycle of a promising drug to cope with future demands for clinical trials and product launch. Possibilities for the reduction of R&D and manufacturing costs are therefore of significant interest in order to be competitive.
In this chapter, four case studies are presented which outline ways to reduce significantly R&D and manufacturing costs by using disposable technology in the frame of a the transfer of an antibody manufacturing process, the preparation of media and buffers in commercial manufacturing and a direct comparison of a traditional and a fully disposable pilot plant.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pavlou AK, Reichert JM (2004) Nat Biotechnol 12:1513
Zika E, Papatryfon I et al (2007) Consequences, opportunities and challenges of modern biotechnology for Europe. Report EUR 22728 EN, http://www.jrc.ec.europa.eu/Accessed 03 January 2008
Lawrence S (2005) Nat Biotechnol 23:1466
Pavlou AK, Belsey M (2005) Eur J Pharm Biopharm 59:389
Walsh G (2006) Nat Biotechnol 7:769
Butler M (2005) Appl Microbiol Biotechnol 68:283
Hodge G (2004) Biopharm Int 3:38
Cardona M, Allen B (2006) Bioprocess Int 4:10
Wrankmore M (2005) Application of disposable technologies in biopharmaceutical manufacturing. BMD Summit, Disposables for Biopharm Production, Reston, VA
Koch A, Wittische C et al (2006) Am Pharm Rev 7:44
Foulon A, Trach F et al (2008) Bioprocess Int 6:6
Acknowledgement
The authors thank all suppliers for providing very valuable information on their disposable systems, making the realization of these projects and theoretical studies possible. The authors also thank Annette Koch, Elodie De Roo, Christelle Laroche-Wittische, Eva Uzan and Gisela Ertel who helped with their previous work to make these case studies possible.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ravisé, A., Cameau, E., De Abreu, G., Pralong, A. (2009). Hybrid and Disposable Facilities for Manufacturing of Biopharmaceuticals: Pros and Cons. In: Eibl, R., Eibl, D. (eds) Disposable Bioreactors. Advances in Biochemical Engineering / Biotechnology, vol 115. Springer, Berlin, Heidelberg. https://doi.org/10.1007/10_2008_24
Download citation
DOI: https://doi.org/10.1007/10_2008_24
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01871-8
Online ISBN: 978-3-642-01872-5
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)